H1B Report
Side-by-side comparison

Deloitte Consulting LLP vs GlaxoSmithKline LLC

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
Deloitte Consulting LLP
PARank #4FEIN 06-1454513
Entity B
GlaxoSmithKline LLC
PARank #FEIN 23-1099050

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricDeloitte Consulting LLPGlaxoSmithKline LLC
Total filings80,813733
Certified %98.23%83.22%
Denied %1.09%0.41%
Withdrawn %0.61%2.05%
Cert-withdrawn %0.07%14.32%
Rank#4
Active yearsFY2010–FY2026FY2010–FY2026
Worksite statePAPA

Outcomes — Deloitte Consulting LLP

DOL case-status mix.

Outcome breakdown: Certified 98.2%, Cert-withdrawn 0.1%, Withdrawn 0.6%, Denied 1.1%
Outcome breakdown
OutcomeShare
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%

Outcomes — GlaxoSmithKline LLC

DOL case-status mix.

Outcome breakdown: Certified 83.2%, Cert-withdrawn 14.3%, Withdrawn 2.1%, Denied 0.4%
Outcome breakdown
OutcomeShare
Certified83.2%
Cert-withdrawn14.3%
Withdrawn2.1%
Denied0.4%
Certified83.2%
Cert-withdrawn14.3%
Withdrawn2.1%
Denied0.4%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

Deloitte Consulting LLP
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,375
FY20113,610
FY20124,716
FY20136,082
FY20147,007
FY20157,572
FY20167,629
FY20177,147
FY201816,089
FY20197,754
FY202052
FY202135
FY202211
FY20231,134
FY20242,702
FY20254,286
FY20262,612
GlaxoSmithKline LLC
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201023
FY201135
FY201248
FY201330
FY201424
FY201547
FY201660
FY201754
FY201855
FY201986
FY202031
FY202140
FY202217
FY202338
FY202459
FY202550
FY202636

Top 5 occupations — Deloitte Consulting LLP

Top 5 occupations — GlaxoSmithKline LLC

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.